Amgen reports data from Sjögren’s Syndrome treatment trial

[cafead]

via Amgen has reported the latest findings from its Phase II clinical trial of the investigational medicine, dazodalibep, to treat patients with Sjögren’s syndrome, an autoimmune disease.

The placebo-controlled, double-blind, randomised, crossover trial is designed to analyse dazodalibep in two Sjögren’s populations.

article source